-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Xeruborbactam in Acinetobacter Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Xeruborbactam in Acinetobacter Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Xeruborbactam in Acinetobacter Infections Drug Details: Xeruborbactam is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Xeruborbactam in Enterobacteriaceae Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Xeruborbactam in Enterobacteriaceae Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Xeruborbactam in Enterobacteriaceae Infections Drug Details: Xeruborbactam is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Xeruborbactam in Pseudomonas aeruginosa Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Xeruborbactam in Pseudomonas aeruginosa Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Xeruborbactam in Pseudomonas aeruginosa Infections Drug Details: Xeruborbactam is under development...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – ORAvance in Gram-Negative Bacterial Infections
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ORAvance in Gram-Negative Bacterial Infections report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ORAvance in Gram-Negative Bacterial Infections Drug Details: ORAvance is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Ceftibuten + Xeruborbactam) in Pyelonephritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Ceftibuten + Xeruborbactam) in Pyelonephritis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Ceftibuten + Xeruborbactam) in Pyelonephritis Drug Details: The fixed dose combination...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ALLO-501A in Diffuse Large B-Cell Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. ALLO-501A in Diffuse Large B-Cell Lymphoma Drug Details: ALLO-501A is under development for the treatment...
-
Product Insights
Pyelonephritis – Drugs In Development, 2023
Global Markets Direct’s, ‘Pyelonephritis - Drugs In Development, 2023’, provides an overview of the Pyelonephritis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Pyelonephritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Acinetobacter Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Acinetobacter Infections - Drugs In Development, 2023’, provides an overview of the Acinetobacter Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Acinetobacter Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Urinary Tract Infections – Drugs In Development, 2023
Global Markets Direct’s, ‘Urinary Tract Infections - Drugs In Development, 2023’, provides an overview of the Urinary Tract Infections pipeline landscape. The report provides comprehensive information on the therapeutics under development for Urinary Tract Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AMX-3009 in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. AMX-3009 in Solid Tumor Drug Details: AMX-3009 is under development for the treatment of HER2...